Cooley advised ERYTECH Pharma on its $143.7 million global offering of an aggregate of 6,180,137 ordinary shares, including the full exercise of the underwriters’ option to purchase additional shares.
The global offering consisted of a US IPO of 5,389,021 American Depositary Shares, each representing one ordinary share and a concurrent private placement in Europe and other countries outside of the US and Canada of 791,116 ordinary shares. Cooley partners Marc Recht, Brian Leaf and Div Gupta led the team advising ERYTECH.
Jefferies acted as global coordinator and joint book-runner for the global offering. Cowen and Company acted as joint book-runner and JMP Securities acted as lead manager for the offering of American Depositary Shares in the US. Oddo BHF SCA acted as joint book-runner for the private placement of ordinary shares in Europe.
ERYTECH was founded in Lyon, France, in 2004; its US headquarters are in Cambridge, Massachusetts. It is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. ERYTECH’s initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival. It now trades on The Nasdaq Global Select Market and Euronext Paris as “ERYP.”
Cooley advised with a team led by Marc Recht (Picture).
Involved fees earner: Marc Recht – Cooley LLP; Brian Leaf – Cooley LLP; Div Gupta – Cooley LLP; Courtney Thorne – Cooley LLP; Francis Wheeler – Cooley LLP; Josh Kaufman – Cooley LLP; Mark Woodroffe – Cooley LLP; Ivor Elrifi – Cooley LLP; Matthew Pavao – Cooley LLP; Geoffrey Spolyar – Cooley LLP; Natasha Leskovsek – Cooley LLP; Phil Mitchell – Cooley LLP; Jeremy Naylor – Cooley LLP; Aaron Pomeroy – Cooley LLP; Stephanie Gentile – Cooley LLP; Kevin King – Cooley LLP; Rebecca Ross – Cooley LLP; Joshua Friedman – Cooley LLP;
Law Firms: Cooley LLP;
Clients: Erytech Pharma;